Table 3 Treatment-related adverse events of the patient population (n = 39) (according to CTCAE v4.03)
Adverse event | Grade 1 | Grade 2 | Grade 3 | Grade 4 |
|---|---|---|---|---|
Leucopenia | 8 (20.5%) | 5 (12.8%) | 2 (5.1%) | 0 |
Anemia | 2 (5.1%) | 1 (2.6%) | 0 | 0 |
Thrombocytopaenia | 2 (5.1%) | 4 (10.3%) | 3 (7.7%) | 1 (2.6%) |
Hyperbilirubinemia | 2 (5.1%) | 1 (2.6%) | 0 | 0 |
Alanine aminotransferase increased | 6 (15.4%) | 2 (5.1%) | 2 (5.1%) | 0 |
Aspartate aminotransferase increased | 7 (17.9%) | 3 (7.7%) | 3 (7.7%) | 1 (2.6%) |
Fever | 10 (25.6%) | 1 (2.6%) | 0 | 0 |
Abdominal pain | 8 (20.5%) | 4 (10.3%) | 0 | 0 |
Nausea/vomiting | 6 (15.4%) | 4 (10.3%) | 0 | 0 |
Abdominal distension | 5 (12.8%) | 6 (15.4%) | 0 | 0 |
Diarrhoea | 2 (5.1%) | 3 (7.7%) | 0 | 0 |
Hypertension | 5 (12.8%) | 5 (12.8%) | 10 (25.6%) | 0 |
Hand-foot syndrome | 9 (23.1%) | 4 (10.3%) | 5 (12.8%) | 0 |
Oral ulcer | 4 (10.3%) | 2 (5.1%) | 0 | 0 |
Proteinuria | 2 (5.1%) | 4 (10.3%) | 3 (7.7%) | 0 |
Sepsis | 0 | 0 | 1 (2.6%) | 0 |
Cholecystitis | 0 | 1 (2.6%) | 0 | 0 |
